---
title: "Psilocybin (COMP360) in Treatment-resistant depression: PsiDeR"
description: "Formulary evidence on Psilocybin (COMP360) in Treatment-resistant depression: PsiDeR. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 40 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence/psider"
published: "2026-11-18T10:42:20-05:00"
modified: "2026-11-18T10:42:20-05:00"
---

# Psilocybin (COMP360) in Treatment-resistant depression: PsiDeR

<a id="heading-3.1.6"></a>

## 3.1.6 PsiDeR

<a id="heading-3.1.6.1"></a>

### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

#### Feasibility of a placebo-controlled randomized design

> “We examined the feasibility of administering a single 25-mg dose of psilocybin or placebo with psychological support in a randomized controlled trial design with 6 weeks of follow-up.”
> “The present trial built upon this pilot, exploring the feasibility of a randomized controlled trial (RCT) design that included a placebo.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.1-2"></a>

#### Primary objective in the protocol

> “The primary objective is to evaluate the feasibility of a randomised, controlled trial design, in which a single dose of psilocybin 25 mg PO versus placebo, is given to adult participants with treatment resistant MDD (TRD), under psychologically supportive conditions, with 6 weeks of follow-up, by measuring recruitment rates, dropout rates and by estimating the variance of the primary outcome measure (Montgomery Asberg Depression Rating Scale (MADRS)) to inform on the design of a phase 3 trial.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.2"></a>

### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

#### Recruitment period and setting

> “Between 21 June 2021 and 3 July 2024, 75 potential participants consented and were screened for eligibility.”
> “Study visits were carried out initially at King’s College Hospital Clinical Research Facility and, subsequently, a refurbished community mental healthcare and research setting in the local community.”
> “Halfway through recruitment, we moved to a refurbished community mental health team setting in a residential area, close to the local hospital.”
> “Recruitment to this trial was severely delayed by the impact of the COVID-19 pandemic, although the trial did recruit to target.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.2-2"></a>

#### Registry dates and location

| Field | Registry entry |
| --- | --- |
| Study start (actual) | “2021-06-21” |
| Primary completion (actual) | “2024-12-18” |
| Study completion (actual) | “2024-12-18” |
| Location | “Clinical Research Facility, King's College Hospital” |

Source: [ClinicalTrials.gov NCT04959253](https://clinicaltrials.gov/study/NCT04959253)

<a id="topic-3.1.6.2-3"></a>

#### Planned trial period in the protocol

> “The trial is taking place between September 2020 and September 2023 in a single centre in London, UK.”
> “Because of the impact of the COVID-19 pandemic, the recruitment period may be extended, subject to necessary approvals.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.3"></a>

### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

#### Single-site, double-blind, placebo-controlled feasibility trial

> “This was a parallel-group, two arm, double-blind, randomized, placebo-controlled phase 2 feasibility trial undertaken at one NHS site in the UK (South London and Maudsley NHS Foundation Trust).”
> “An open-label extension was also offered to all participants, lasting a further 12 weeks after the 6-week RCT follow-up period.”
> “The sponsor of the trial was the South London and Maudsley NHS Foundation Trust and King’s College London.”
> “COMP360 psilocybin—a proprietary, pharmaceutical-grade synthetic psilocybin formulation—and matching placebo capsules were supplied by COMPASS Pathfinder Ltd., a subsidiary of COMPASS Pathways plc, which had no role in the design, conduct or analysis of the study.”
> “This trial was funded by the National Institute for Health and Care Research (NIHR) Clinician Scientist Programme (CS-2017-17-007).”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.3-2"></a>

#### Randomization by minimization and masking

> “Participants were randomized (1:1) to receive 25-mg psilocybin or placebo, with the sequence generated using minimization by sex (male, female), age (25−59, ≥60) and past psilocybin use (yes, no), by a web-based service hosted by the King’s Clinical Trials Unit (KCTU) and concealed from the trial team.”
> “Participants, researchers and the senior statistician (B.C.) were masked to treatment allocation until database lock.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.3-3"></a>

#### Choice of an inactive placebo

> “An inactive placebo control allows for a better characterization of safety signals in psychedelic trials and does not adversely affect feasibility aims; hence, it was chosen for this trial”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “In discussion with the funders of this trial, we decided to use a true placebo control to measure the difference in AE rate and the variance in the primary depression outcome measure without the difficulties implied by an active control.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.4"></a>

### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

#### Inclusion criteria: age, depression severity, and prior treatment

> “Eligibility criteria for participants included age 25−80 years, fluency in English, meeting DSM-5 criteria for a current episode of MDD, a 17-item Hamilton Depression Rating Scale (HAM-D-17)”
> “score of ≥14 and an inadequate response to ≥2 therapeutic antidepressant trials or ≥1 antidepressant trial and ≥1 psychotherapy trial.”
> “There was no upper limit on the number or type of previous treatments permitted.”
> “For those aged ≥60 years, the first episode of depression must have started prior to their 60th birthday.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.4-2"></a>

#### Exclusion criteria

> “Exclusion criteria included a DSM-5 diagnosis of bipolar disorder, psychotic disorder, drug or alcohol dependence syndrome, personality disorder or dementia; suicide attempt in the past year; any clinically significant medical diagnoses or biochemical or electrocardiographic abnormalities deemed incompatible with psilocybin treatment; personal circumstances or behavior judged to be incompatible with establishment of rapport or safe exposure to psilocybin; women of childbearing potential not using adequate contraception; women who were pregnant or breastfeeding; those unable to give informed consent; those enrolled in another drug trial; and hypersensitivity to the investigational medicinal product, any of the excipients or placebo.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.5"></a>

### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

#### Single 25 mg dose of COMP360 or matched placebo

> “COMP360 psilocybin and placebo were administered as five capsules, matched for appearance, weight, color, texture and smell.”
> “Participants self-administered either 25-mg COMP360 psilocybin or placebo via oral administration.”
> “Participants were accompanied by a therapist and chaperone for approximately 6 hours within a quiet room with a bed and adjustable lighting within the research facility.”
> “Participants were given an optional eye mask and earphones through which they listened to a curated playlist of music.”
> “A trial doctor determined suitability for discharge at the end of the day.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.5-2"></a>

#### Withdrawal of antidepressants and psychological preparation

> “Participants determined eligible at screening (V1) entered a screening and preparation phase (lasting 1−8 weeks), during which they were withdrawn from antidepressant, antipsychotic or mood-stabilizing drugs and had sessions of psychological preparation and psychoeducation with a trial therapist.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.5-3"></a>

#### Integration therapy and open-label extension

> “For 6 weeks after the dosing visit, participants met with the study team to complete follow-up assessments and engage in time-limited integration therapy (1 day (V4), 1 week (V5), 3 weeks (V6) and 6 weeks (V7) after dosing).”
> “As part of the extended design of this trial, at 6-week follow-up all eligible participants were invited to take part in a 12-week open-label extension, the results of which will be published elsewhere.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.6"></a>

### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

#### 3.1.6.6.1 Rationale for Using Recruitment and Retention Rates as the Primary Endpoint

<a id="topic-3.1.6.6.1-1"></a>

##### Primary feasibility outcomes

> “Primary outcomes were measures of feasibility: recruitment rates, dropout rates and an estimate of the variance of the MADRS”
> “The study was designed as a feasibility study to estimate the dropout rate (20%) with a 95% CI of ±10.1% (9.9−30.1%).”
> “No hypothesis testing was undertaken.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.6.1-2"></a>

##### Rationale in the protocol: acceptability of a placebo-controlled design and variance for a future efficacy trial

> “However, this study was not blinded and did not have a placebo control group.”
> “Furthermore, it could not be determined from the open label design whether a randomised, placebo-controlled design investigating psilocybin would be acceptable to patients with TRD.”
> “A further purpose of this trial was to estimate the variance of the primary outcome measure between groups to inform a power calculation for a future efficacy trial.”
> “Allows a robust measurement of the variance in the primary outcome measure between groups to inform an efficacy trial.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.6.1-3"></a>

##### Feasibility parameters reported

> “To evaluate recruitment and other feasibility parameters, the following are reported alongside 95% CIs: proportion eligible out of number screened; proportion randomized out of number consented; proportion completing at least the MADRS at each follow-up visit out of number randomized (overall and by arm); proportion attending the dosing visit out of number randomized (overall and by arm); and proportion receiving all five capsules/tablets out of number randomized (overall and by arm).”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.6.1-4"></a>

##### Depression outcome: MADRS by blinded independent raters at Week 3

> “The primary outcome measure for depression is the Montgomery Asberg Depression Rating Scale collected by blinded, independent raters.”
> “The primary endpoint is at 3 weeks, and the total follow-up is 6 weeks.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.6.1-5"></a>

##### Secondary clinical outcomes

> “Secondary outcomes at weeks 1, 3 and 6 follow-up included MADRS total scores; proportions of participants in each group who met criteria for clinician-rated response to treatment (defined as a ≥50% decrease in MADRS score from baseline) and remission (defined as a MADRS score ≤10)”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.7"></a>

### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

#### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

##### Target sample size and its basis

> “The target sample size was 60 participants.”
> “All 60 participants were included in primary feasibility analyses.”
> “One participant withdrew in the placebo arm before contributing follow-up MADRS data and was, thus, excluded from mixed models.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “Since the study is exploratory, formal sample size calculations were not undertaken.”
> “The sample size selected was informed by published work that models processes of parameter estimates for continuous measures from early phase trials.”
> “This is considered sufficient to test the intervention and provide adequately reliable estimates of recruitment rate and loss to follow-up.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="heading-3.1.6.7.2"></a>

#### 3.1.6.7.2 Description of Analysis Sets

<a id="topic-3.1.6.7.2-1"></a>

##### Intention-to-treat analysis and mixed models

> “Analyses were intention to treat: all participants were analyzed as randomized.”
> “For secondary continuous clinical outcomes, the adjusted mean difference between arms was estimated in mixed-effects linear regression models.”
> “Follow-up values were fit simultaneously and predicted by the fixed effects of trial arm, baseline assessment, minimization factors (sex, age group, prior psilocybin use), time (categorical) and an arm × time interaction term to allow estimates of the treatment effect at each follow-up point.”
> “Secondary binary outcomes were analyzed using mixed-effects logistic regression models with random intercept at the participant level and adjusting for the fixed effects, as stated previously.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.7.2-2"></a>

##### Missing data

> “No multiple imputation was done for missing follow-up measurements.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8"></a>

### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

#### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

##### Screening, randomization, and withdrawal

> “Sixty participants were randomized to either psilocybin or placebo arms; 30 participants were allocated to each arm”
> “Of 75 participants consented and screened, 62 were eligible (83%, 95% confidence interval (CI): 72−90%), and 60 were randomized (80%, 95% CI: 69−88%).”
> “All randomized participants attended the dosing visit, and 59 of 60 participants completed the MADRS at each timepoint, as the only missing observation was the one participant in the placebo arm who had withdrawn prior to week 1.”
> “One participant withdrew from the placebo arm; the participant no longer wished to participate for personal reasons.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.2"></a>

#### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

##### Minimization factors and baseline demographics by arm

| Characteristic | Placebo (N = 30) | Psilocybin (N = 30) | Overall (N = 60) |
| --- | --- | --- | --- |
| Female, n (%) | “15 (50%)” | “15 (50%)” | “30 (50%)” |
| Age group 60 or older, n (%) | “3 (10%)” | “3 (10%)” | “6 (10%)” |
| Past psilocybin use, n (%) | “5 (17%)” | “4 (13%)” | “9 (15%)” |
| Age at randomization, median (IQR) | “40.2 (33.7−52.0)” | “41.7 (38.6−57.0)” | “40.8 (35.2−52.3)” |
| HAM-D-17 score, median (IQR) | “17.0 (15.0−21.0)” | “18.5 (16.0−21.0)” | “18.0 (15.0−21.0)” |
| Ethnicity White, n (%) | “24 (80%)” | “21 (70%)” | “45 (75%)” |
| Postgraduate degree, n (%) | “14 (47%)” | “11 (37%)” | “25 (42%)” |
| Full-time employed, n (%) | “11 (37%)” | “15 (50%)” | “26 (43%)” |
| First-degree family history of depression, n (%) | “15 (50%)” | “18 (60%)” | “33 (55%)” |
| Years spent with feelings of significant depression, mean (s.d.) | “19.2 (10.3)” | “20.9 (10.2)” | “20.0 (10.2)” |
| Maudsley Staging Method score at screening, median (IQR) | “8.0 (7.0−9.0)” | “8.0 (7.0−10.0)” | “8.0 (7.0−9.5)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.2-2"></a>

##### Treatment resistance and chronicity

> “Median Maudsley Staging Method (MSM) scores at screening indicated that most participants scored within the moderate range for treatment resistance, with a chronic course of illness.”
> “On average, patients in this trial had been ill for 20 years and showed moderate levels of treatment resistance.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.3"></a>

#### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

##### Primary feasibility outcomes

| Feasibility parameter | Numbers | Proportion (95% CI) |
| --- | --- | --- |
| Participation rate (enrolled / approached) | “75 / 165” | “46% (38−53%)” |
| Eligibility rate (eligible / consented to screening) | “62 / 75” | “83% (72−90%)” |
| Randomization rate (randomized / consented) | “60 / 75” | “80% (69−88%)” |
| Dosing visit attendance, overall | “60 / 60” | “100% (94%)” |
| Week 3 MADRS completion, placebo | “29 / 30” | “97% (83−100%)” |
| Week 3 MADRS completion, psilocybin | “30 / 30” | “100% (88%)” |
| Week 6 MADRS completion, overall | “59 / 60” | “98% (91−100%)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “No success metrics were set, but eligibility and randomization rates were high.”
> “The 97.5% one-sided CI (with an upper bound of infinity) is given if the proportion was 100%.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.3-2"></a>

##### MADRS adjusted mean difference between arms

| MADRS timepoint (n = 59) | Mean difference (95% CI) | Cohen's d (95% CI) |
| --- | --- | --- |
| Week 1 | “−11.44 (−15.89 to −6.98)” | “−1.87 (−2.59 to −1.14)” |
| Week 3 | “−10.41 (−14.86 to −5.95)” | “−1.7 (−2.42 to −0.97)” |
| Week 6 | “−12.92 (−17.37 to −8.47)” | “−2.11 (−2.83 to −1.38)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

> “At week 3, the between-group difference in the MADRS was −10.41 (95% CI: −14.86 to −5.95), indicating a clinically significant improvement in depression in the psilocybin arm compared to the placebo arm.”
> “The between-group difference in the MADRS at week 3 was sustained at week 6, with an adjusted mean difference of −12.92 points (95% CI: −17.37 to −8.47).”
> “Cohen’s d is the mean difference between arms divided by pooled baseline standard deviation.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.3-3"></a>

##### MADRS response and remission

> “At week 3, 1 (3%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met the cutoff for MADRS response, and 1 (3%) in the placebo arm and 12 (40%) in the psilocybin arm met the cutoff for MADRS remission.”
> “These figures were sustained at week 6; however MADRS response increased to 15 (50%) participants in the psilocybin arm.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.4"></a>

#### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.6.8.4-1"></a>

##### Adjusted mean differences in patient-reported outcomes

| Scale and timepoint | Mean difference (95% CI) | Cohen's d (95% CI) |
| --- | --- | --- |
| QIDS-SR-16, Week 3 | “−5.48 (−7.85 to −3.12)” | “−1.19 (−1.7 to −0.67)” |
| QIDS-SR-16, Week 6 | “−5.63 (−8.00 to −3.27)” | “−1.22 (−1.73 to −0.71)” |
| GAD-7, Week 3 | “−4.85 (−6.96 to −2.74)” | “−1.00 (−1.44 to −0.57)” |
| GAD-7, Week 6 | “−4.54 (−6.64 to −2.44)” | “−0.94 (−1.37 to −0.50)” |
| EQ-5D-5L VAS, Week 3 | “12.46 (3.39−21.54)” | “0.62 (0.17−1.07)” |
| EQ-5D-5L VAS, Week 6 | “10.69 (1.63−19.75)” | “0.53 (0.08−0.98)” |
| WSAS, Week 3 | “−8.20 (−12.09 to −4.30)” | “−1.26 (−1.86 to −0.66)” |
| WSAS, Week 6 | “−9.22 (−13.08 to −5.36)” | “−1.42 (−2.02 to −0.83)” |
| M3VAS, Week 3 | “45.33 (19.69−70.96)” | “1.17 (0.51−1.83)” |
| M3VAS, Week 6 | “36.42 (10.80−62.04)” | “0.94 (0.28−1.60)” |
| WEMWBS, Week 3 | “10.48 (6.57−14.40)” | “1.76 (1.10−2.42)” |
| WEMWBS, Week 6 | “9.44 (5.55−13.32)” | “1.59 (0.93−2.24)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.4-2"></a>

##### Self-reported depression response and remission

> “At week 3, no participants in the placebo arm met criteria for Quick Inventory of Depressive Symptomatology Self-Report 16-item version (QIDS-SR-16) response compared to 15 (50%) in the psilocybin arm.”
> “At week 6, one (4%) participant in the placebo arm and 13 (43%) participants in the psilocybin arm met QIDS-SR-16 response.”
> “One participant (4%) in the placebo arm and 12 (40%) participants in the psilocybin arm met the cutoff for QIDS-SR-16 remission at week 3 compared to two (7%) in the placebo arm and 10 (33%) in the psilocybin arm at week 6.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.4-3"></a>

##### Anxiety, health state, functioning, and wellbeing

> “at week 6, 5 of 30 (17%) psilocybin participants had GAD-7 scores ≥10 compared with 18 out of 29 (62%) placebo participants.”
> “Self-reported depression severity was improved in the psilocybin arm compared to placebo at all follow-up timepoints, as were ratings of anxiety, overall health state, psychopathology and mental wellbeing.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.8.5"></a>

#### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

##### Nonserious adverse events during the randomized phase (randomization to Week 6)

| Category | Placebo (123 events; 28 reporters) | Psilocybin (164 events; 30 reporters) | Overall (287 events; 58 reporters) |
| --- | --- | --- | --- |
| Neurological, events (reporters) | “32 (17)” | “53 (26)” | “85 (43)” |
| Mood/psychological, events (reporters) | “13 (9)” | “30 (18)” | “43 (27)” |
| Respiratory infection, events (reporters) | “24 (16)” | “12 (11)” | “36 (27)” |
| Gastrointestinal, events (reporters) | “8 (6)” | “15 (12)” | “23 (18)” |
| Musculoskeletal/pain, events (reporters) | “13 (11)” | “14 (9)” | “27 (20)” |
| Medication or substance related, events (reporters) | “5 (5)” | “10 (9)” | “15 (14)” |
| General fatigue/tiredness, events (reporters) | “4 (4)” | “8 (8)” | “12 (12)” |
| Related to study medication, n (%) | “2 (2%)” | “29 (18%)” | “31 (11%)” |
| Possibly related, n (%) | “16 (13%)” | “56 (34%)” | “72 (25%)” |
| Mild intensity, n (%) | “77 (63%)” | “111 (68%)” | “188 (66%)” |
| Moderate intensity, n (%) | “45 (37%)” | “48 (29%)” | “93 (32%)” |
| Severe intensity, n (%) | “1 (1%)” | “5 (3%)” | “6 (2%)” |
| Adverse events of special interest, n (%) | “0 (0%)” | “0 (0%)” | “0 (0%)” |

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.5-2"></a>

##### Serious adverse events and relatedness

> “In total, 287 nonserious AEs (123 in the placebo arm, 164 in the psilocybin arm) were recorded in the RCT phase”
> “Four SAEs (one in the placebo arm, three in the psilocybin arm) were recorded: three during the open-label phase and one during the RCT phase”
> “Over half of nonserious AEs (184 out of 287, 64%) were not related to study medication, and all but one SAE was deemed not related to study medication.”
> “The remaining event, which occurred in the placebo arm, was deemed as possibly related.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.8.5-3"></a>

##### Suicidality and mania

> “Psilocybin administration was well tolerated: AEs were mostly mild in severity and resolved by the end of the trial, and clinical safety scales measuring suicidality and mania did not show substantial changes across time.”
> “In the present study, the proportion of patients reporting suicidal ideation on the Columbia−Suicide Severity Rating Scale (C−SSRS) was similar at baseline and at week 3 and week 6 follow-up, after an initial reduction at day 1 and week 1.”
> “Proportions also appeared similar across arms.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="heading-3.1.6.9"></a>

### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

#### Summary: functional unblinding, inactive placebo with little placebo response, feasibility design, single site, sample composition

PsiDeR was a single-site feasibility trial of 60 participants with 6 weeks of follow-up and no hypothesis testing. Blinding was assessed in a subsample of 23 participants after a measure was introduced part-way through the trial: 13 of 13 (100%) in the psilocybin arm and 7 of 10 (70%) in the placebo arm correctly guessed their allocation, and the authors state that “expectancy effects in both groups likely account for some of the between-group difference observed”. The placebo arm did not show meaningful reductions in MADRS or QIDS-SR scores, and the authors note that active placebos or subperceptual doses may be more appropriate for efficacy trials. The sample was highly educated, recruitment targets were not met for Black, African, Caribbean or Black British participants, and about half of participants used facilities opened under a later financial agreement with COMPASS Pathways.

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-2"></a>

#### Functional unblinding and expectancy

> “Blinding was not upheld, with 100% of participants who received psilocybin and 70% of participants who received placebo correctly guessing their allocation.”
> “Thus, expectancy effects in both groups likely account for some of the between-group difference observed.”
> “Functional unblinding due to the subjective effects of psilocybin is an obvious limitation of this trial, as it is with all trials of drugs that have noticeable effects, as well as many psychological and behavioral interventions.”
> “However, we used raters who were independent of the trial team to measure the primary outcome in this trial, and participants were asked not to discuss their beliefs about their allocation with the raters.”
> “Despite this, the limited assessment of blinding is a weakness of this trial.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-3"></a>

#### Blinding assessed in a subsample

> “The adequacy of participant blinding was assessed using self-report visual analog scales of group allocation confidence, introduced part-way through the trial and, therefore, collected in only a subsample of participants.”
> “Of the 23 participants who were asked, n = 13 out of 13 (100%) in the psilocybin arm and n = 7 out of 10 (70%) in the placebo arm correctly guessed their treatment allocation.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-4"></a>

#### Absence of placebo response and choice of control

> “However, a part of this effect is likely attributable to a lack of response or remission in the placebo arm, with total MADRS and QIDS-SR scores not showing meaningful reductions across time.”
> “However, other trial designs (that is, active placebos or subperceptual doses of the study drug) may be more appropriate for efficacy trials and will be considered in the design of a future trial”
> “found more modest effect sizes comparing 1-mg to 25-mg psilocybin at week 3 than in the present trial.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-5"></a>

#### Sample composition and generalizability

> “We largely met our recruitment targets in all ethnic groups, apart from in Black, African, Caribbean or Black British participants.”
> “We note that our sample population is highly educated, with much higher proportions of participants with university degrees than in the general population.”
> “Together, these results suggest that a single dose of psilocybin may reduce depressive symptoms in MDD and TRD, although larger, and longer, scale studies are required to confirm the nature and durability of these effects.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

<a id="topic-3.1.6.9-6"></a>

#### Single centre and rater independence in the protocol

> “As this is a single-centre study, the findings are unlikely to be generalisable beyond the trial setting.”
> “While raters of the primary outcome are independent of the study team, they are not independent of the institution undertaking the research.”

Source: [Rucker et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8638462/)

<a id="topic-3.1.6.9-7"></a>

#### Relationship between the trial facilities and COMPASS Pathways

> “Although COMPASS Pathways did not financially support this study, a separate financial agreement 4 years subsequent to this study being funded resulted in the opening of the Centre for Mental Health Research and Innovation, the facilities of which were used (without cost) for about half of the participants in this study.”

Source: [Rucker et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13577891/)

## Related pages
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Terms and abbreviations](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/terms-and-abbreviations.md)
- [Psilocybin (COMP360): Treatment-resistant depression](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/executive-summary.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Product information and disease description](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/product-information-and-disease-description.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Clinical evidence](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/clinical-evidence.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: Economic information and modeling report](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/economics.md)
- [Psilocybin (COMP360) in Treatment-resistant depression: References](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references) · [Markdown](https://www.evicenter.com/drugs/psilocybin--treatment-resistant-depression/references.md)
